drugset / Trial / NCT02138136

Lubiprostone for Children With Constipation

NCT02138136

Phase 3 Completed 419 enrolled Sucampo Pharma Americas, LLC Takeda · collab
NaSingle-groupOpen-labelTreatment

Summary

This study is for children with constipation. Children who completed 3 months of treatment in the earlier study (NCT02042183): * were invited to participate * will receive lubiprostone for 9 more months * will see if lubiprostone safely relieves their constipation if taken for a whole year

Timeline

Start
2014-02-26
Primary completion
2017-05-01
Completion
2017-05-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Lubiprostone Small molecule 12 ug Oral
Subject Lubiprostone Small molecule 24 ug Oral

Indications